Scientific evidence on eggshell membrane and accumulated joint research
First written in FY2021. 13 of 20 entries say "Restated". Latest entry: 2026-11-13.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「January 2026: Results of joint research by the University of Tokyo and the company published online in the academic journal “Bioscience Reports” April 2026: Results of joint research by Toyo University and the company published online in the academic journal “Tissue and Cell”」
The company newly disclosed publications in January and April 2026 of joint research results with the University of Tokyo and Toyo University. Research and development expenses for the fiscal year were ¥93.062 million, and details of research with the University of Tokyo, Teikyo University, Toyo University and Yonago National College of Technology were also provided. - FY2026-H1RestatedAnnual report
「The amount spent on research and development activities during the interim accounting period was ¥47.224 million. There were no material changes in the status of the company's research and development activities during the interim accounting period.」
The company disclosed research and development expenses of ¥47.224 million and stated that there were no material changes in the status of its research and development activities. - FY2025AdvancedAnnual report
「Total research and development expenses for the fiscal year were ¥94.804 million.」
The company disclosed research and development expenses of ¥94.804 million and provided details of its research with Teikyo University, the University of Tokyo, Toyo University and Yonago National College of Technology. It also entered into joint research agreements with Yonago National College of Technology in March 2024 and Toyo University in April 2024. - FY2025-H1RestatedAnnual report
「The amount spent on research and development activities during the interim accounting period was ¥46.730 million. There were no material changes in the status of the company's research and development activities during the interim accounting period.」
The company disclosed research and development expenses of ¥46.730 million and stated that there were no material changes in the status of its research and development activities. - FY2024-Q3RestatedAnnual report
「The amount spent on research and development activities during the third cumulative quarter was ¥43.316 million. There were no material changes in the status of the company's research and development activities during the third cumulative quarter.」
The company disclosed research and development expenses of ¥43.316 million and stated that there were no material changes in the status of its research and development activities. - FY2024-Q2RestatedAnnual report
「The amount spent on research and development activities during the second cumulative quarter was ¥30.475 million. There were no material changes in the status of the company's research and development activities during the second cumulative quarter.」
The company disclosed research and development expenses of ¥30.475 million and stated that there were no material changes in the status of its research and development activities. - FY2024-Q1RestatedAnnual report
「The amount spent on research and development activities during the first cumulative quarter was ¥13.175 million. There were no material changes in the status of the company's research and development activities during the first cumulative quarter.」
The company disclosed research and development expenses of ¥13.175 million and stated that there were no material changes in the status of its research and development activities. - FY2023RestatedAnnual report
「The company has entered into agreements concerning joint research with several universities and other research institutions to investigate the potential of eggshell membrane as a material, the primary raw material in its products.」
The company continued joint research with the University of Tokyo and Tokyo University of Agriculture and Technology and recorded research and development expenses of ¥89.652 million for the fiscal year. No specific new results, such as publication in a new academic journal, were reported. - FY2023-Q3RestatedAnnual report
「The amount spent on research and development activities during the third cumulative quarter was ¥67.840 million. There were no material changes in the status of the company's research and development activities during the third cumulative quarter.」
The company disclosed research and development expenses of ¥67.840 million and stated that there were no material changes in the status of its research and development activities. - FY2023-Q2RestatedAnnual report
「The amount spent on research and development activities during the second cumulative quarter was ¥43.272 million. There were no material changes in the status of the company's research and development activities during the second cumulative quarter.」
The company disclosed research and development expenses of ¥43.272 million and stated that there were no material changes in the status of its research and development activities. - FY2023-Q1RestatedAnnual report
「The amount spent on research and development activities during the first cumulative quarter was ¥21.980 million. There were no material changes in the status of the company's research and development activities during the first cumulative quarter.」
The company disclosed research and development expenses of ¥21.980 million and stated that there were no material changes in the status of its research and development activities. - FY2022AdvancedAnnual report
「June 2021: Results of joint research by the University of Tokyo and the company published online in the academic journal “Nutrients” October 2021: Results of joint research by the University of Tokyo and the company published online in the academic journal “Journal of Fiber Science and Technology”」
The company specifically disclosed new publications of joint research results in academic journals. Research and development expenses for the fiscal year were ¥88.194 million, and research with the University of Tokyo and Tokyo University of Agriculture and Technology is continuing. - FY2022-Q3RestatedAnnual report
「The amount spent on research and development activities during the third cumulative quarter was ¥66.778 million. There were no material changes in the status of the company's research and development activities during the third cumulative quarter.」
The company disclosed research and development expenses of ¥66.778 million and stated that there were no material changes in the status of its research and development activities. - FY2022-Q2RestatedAnnual report
「The amount spent on research and development activities during the second cumulative quarter was ¥44.335 million. There were no material changes in the status of the company's research and development activities during the second cumulative quarter.」
The company disclosed research and development expenses of ¥44.335 million and stated that there were no material changes in the status of its research and development activities. - FY2022-Q1RestatedAnnual report
「The amount spent on research and development activities during the first cumulative quarter was ¥21.380 million. There were no material changes in the status of the company's research and development activities during the first cumulative quarter.」
The company disclosed the amount spent on research and development activities and stated that there were no material changes in the status of those activities. - FY2021First statedAnnual report
「Our Planning and Manufacturing Department conducts joint research with universities and other research institutions. We have also entered into a business outsourcing agreement with our founder, Hasebe Yukio (長谷部 由紀夫), for advice regarding business partners and other matters (contract period: October 2020 to September 2021). By investigating the various potential applications of eggshell membrane as a material, we are exploring uses not only in cosmetics and health foods but also in other fields. Total research and development expenses for the fiscal year were ¥88.318 million.」
The company is researching health benefits, topical effects and mechanisms through joint research with the University of Tokyo, Tokyo University of Agriculture and Technology and other institutions.